Outlook Therapeutics' ONS-5010 Eyes FDA Approval
Update: 2025-11-13
Description
Outlook Therapeutics stock surged 17% after FDA accepted their new application for ONS-5010, a potential wet AMD treatment. The FDA will review the application for 60 days, with a target decision date of December 31, 2023. If approved, ONS-5010 could be the first FDA-approved eye-specific bevacizumab formulation for wet AMD in the US.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
